Q3 2025 Earnings Call Transcript October 30, 2025 DexCom, Inc. beats earnings expectations. Reported EPS is $0.61, ...

DexCom, Inc. DXCM reported third-quarter 2025 adjusted earnings per share (EPS) of 61 cents, which beat the Zacks Consensus ...

DXCM's Q3 results are likely to benefit from rising G7 use, early Stelo traction and expanding access across Type 2 diabetes ...

People with Type 1 diabetes are estimated to make up to 180 more decisions a day than someone without the disease, according to a study from Stanford University. Each meal, workout, or night’s sleep ...

Thank you, operator, and welcome to DexCom's Third Quarter 2025 Earnings Call. Our agenda begins with Jake Leach, DexCom's President and Interim CEO, who will summarize our recent highlights and ...

DexCom, Inc. DXCM is scheduled to report third-quarter 2025 resultson Oct. 30, after the closing bell. In the last reported quarter, the company’s adjusted earnings per share (EPS) of 48 ...

After dealing with a deployment problem with glucose monitors earlier this year, interim CEO Jake Leach said improving ...

DexCom posts Q3 revenue of $1.21 billion, beating estimates and raising 2025 guidance as analysts expect strong sales and margin improvement ahead.

Get key insights from DexCom’s Q3 2025 earnings: robust revenue growth, new product launches, updated guidance, and future opportunities.

Amid some scrutiny over its latest-generation G7 CGM, Dexcom officials addressed claims on the company's latest earnings call ...

Dexcom (Nasdaq:DXCM) shares took a hit after hours today on third-quarter results that came in ahead of the consensus ...